Citations (207)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Joydeep Chakraborty, Atanu Maity & Hironmoy Sarkar. (2023) A systematic drug repurposing approach to identify promising inhibitors from FDA-approved drugs against Nsp4 protein of SARS-CoV-2. Journal of Biomolecular Structure and Dynamics 41:2, pages 550-559.
Read now
Read now
Negar Firouzabadi, Niloofar Navabzadeh, Ebrahim Moghimi-Sarani & Maral Haghnegahdar. (2020) Orexin/Hypocretin Type 2 Receptor (HCRTR2) Gene as a Candidate Gene in Sertraline-Associated Insomnia in Depressed Patients. Neuropsychiatric Disease and Treatment 16, pages 1121-1128.
Read now
Read now
Matthew Chow & Michelle Cao. (2016) The hypocretin/orexin system in sleep disorders: preclinical insights and clinical progress. Nature and Science of Sleep 8, pages 81-86.
Read now
Read now
Joyce K Lee-Iannotti & James M Parish. (2016) Suvorexant: a promising, novel treatment for insomnia. Neuropsychiatric Disease and Treatment 12, pages 491-495.
Read now
Read now
Donghui Cui, Tamara Cabalu, Ka Lai Yee, James Small, Xiaodong Li, Bo Liu, Cheri Maciolek, Sheri Smith, Wen Liu, Jacqueline B. McCrea & Thomayant Prueksaritanont. (2016) In vitro and in vivo characterisation of the metabolism and disposition of suvorexant in humans. Xenobiotica 46:10, pages 882-895.
Read now
Read now
Terrence McDonald, Hongyu A. Liang, Raul Sanoja, Anthony L. Gotter, Scott D. Kuduk, Paul J. Coleman, Karen M. Smith, Christopher J. Winrow & John J. Renger. (2016) Pharmacological evaluation of orexin receptor antagonists in preclinical animal models of pain. Journal of Neurogenetics 30:1, pages 32-41.
Read now
Read now
Abdelaziz Ghanemi & Xintian Hu. (2015) Targeting the orexinergic system: Mainly but not only for sleep-wakefulness therapies. Alexandria Journal of Medicine 51:4, pages 279-286.
Read now
Read now
Laura H Jacobson, Gabrielle E Callander & Daniel Hoyer. (2014) Suvorexant for the treatment of insomnia. Expert Review of Clinical Pharmacology 7:6, pages 711-730.
Read now
Read now
Ronald A. Miller, Christopher J. Winrow, Daniel S. Spellman, Qinghua Song, Duane R. Reiss, James P. Conway, Rhonda R. Taylor, Paul J. Coleman, Ronald C. Hendrickson & John J. Renger. (2014) Quantitative Proteomics in Laser Capture Microdissected Sleep Nuclei From Rat Brain. Journal of Neurogenetics 28:1-2, pages 136-145.
Read now
Read now
John A Christopher & Miles S Congreve. (2013) Treatment and prevention of various therapeutic conditions using OX receptor antagonistic activity (WO2012081692). Expert Opinion on Therapeutic Patents 23:2, pages 273-277.
Read now
Read now
John J. Renger & Jonathan T. Kern. (2011) Preface to the Special Issue “Novel Pharmaconeurogenetic Approaches Arising from Progress in Translational Genetics”. Journal of Neurogenetics 25:4, pages 117-119.
Read now
Read now
Joseph I. Brunner, Anthony L. Gotter, Joshua Millstein, Susan Garson, Jacquelyn Binns, Steven V. Fox, Alan T. Savitz, He S. Yang, Karrie Fitzpatrick, Lili Zhou, Joseph R. Owens, Andrea L. Webber, Martha H. Vitaterna, Andrew Kasarskis, Victor N. Uebele, Fred Turek, John J. Renger & Christopher J. Winrow. (2011) Pharmacological Validation of Candidate Causal Sleep Genes Identified in an N2 Cross. Journal of Neurogenetics 25:4, pages 167-181.
Read now
Read now
Articles from other publishers (195)
Carol A. Everson, Aniko Szabo, Cade Plyer, Thomas A. Hammeke, Brian D. Stemper & Mathew D. Budde. (2024) Sleep loss, caffeine, sleep aids and sedation modify brain abnormalities of mild traumatic brain injury. Experimental Neurology 372, pages 114620.
Crossref
Crossref
Michel A Steiner, Michael Toeroek-Schafroth, Maria-Elena Giusepponi, Lisa Dacome & Michela Tessari. (2023) Abuse potential assessment of the dual orexin receptor antagonist daridorexant in rats. Journal of Psychopharmacology.
Crossref
Crossref
Shoya Ikeuchi, Rei Tanaka, Teiichi Sugiura, Kaori Shinsato, Akane Wakabayashi, Junya Sato, Keiko Suzuki & Michihiro Shino. (2023) Efficacy of combined use of Suvorexant and Ramelteon in preventing postoperative delirium: a retrospective comparative study. Journal of Pharmaceutical Health Care and Sciences 9:1.
Crossref
Crossref
Michel A Steiner, Michael Toeroek-Schafroth, Lisa Dacome & Michela Tessari. (2023) Failure of the dual orexin receptor antagonist suvorexant to engender drug discrimination in rats. Journal of Psychopharmacology.
Crossref
Crossref
Laura Palagini, Pierre A. Geoffroy, Matteo Balestrieri, Mario Miniati, Giovanni Biggio, Claudio Liguori, Danilo Menicucci, Luigi Ferini‐Strambi, Lino Nobili, Dieter Riemann & Angelo Gemignani. (2023) Current models of insomnia disorder: a theoretical review on the potential role of the orexinergic pathway with implications for insomnia treatment. Journal of Sleep Research 32:4.
Crossref
Crossref
Erik Schéle, Iris Stoltenborg, Anders Xie, Fiona Peris-Sampedro, Roger A.H. Adan & Suzanne L. Dickson. (2023) Engagement of the brain orexin system in activity-based anorexia behaviour in mice. European Neuropsychopharmacology 70, pages 63-71.
Crossref
Crossref
Kazumaro Okino, Hirohisa Suzuki, Hiroi Tomioka, Kenji Sanada, Keita Kawai, Akira Iwanami & Atsuko Inamoto. (2023) Efficacy and safety of lemborexant as an alternative drug for patients with insomnia taking gamma‐aminobutyric acid–benzodiazepine receptor agonists or suvorexant. Human Psychopharmacology: Clinical and Experimental 38:3.
Crossref
Crossref
Jessica M. Illenberger, Francisco J. Flores-Ramirez, Alessandra Matzeu, Barbara J. Mason & Rémi Martin-Fardon. (2023) Suvorexant, an FDA-approved dual orexin receptor antagonist, reduces oxycodone self-administration and conditioned reinstatement in male and female rats. Frontiers in Pharmacology 14.
Crossref
Crossref
Christopher Daniel Morrone, Radha Raghuraman, S. Abid Hussaini & Wai Haung Yu. (2023) Proteostasis failure exacerbates neuronal circuit dysfunction and sleep impairments in Alzheimer’s disease. Molecular Neurodegeneration 18:1.
Crossref
Crossref
Wojciech Ziemichód, Antonina Kurowska, Karolina Grabowska, Michalina Kurowska & Grażyna Biała. (2023) Characteristics of Seltorexant—Innovative Agent Targeting Orexin System for the Treatment of Depression and Anxiety. Molecules 28:8, pages 3575.
Crossref
Crossref
Neha & Suhel Parvez. (2023) Emerging therapeutics agents and recent advances in drug repurposing for Alzheimer’s disease. Ageing Research Reviews 85, pages 101815.
Crossref
Crossref
Naoya Nishino, Taisuke Ono & Seiji Nishino. 2023. Encyclopedia of Sleep and Circadian Rhythms. Encyclopedia of Sleep and Circadian Rhythms
314
324
.
Seiji Nishino. 2023. Encyclopedia of Sleep and Circadian Rhythms. Encyclopedia of Sleep and Circadian Rhythms
17
29
.
S. Harris, M.J. Thorpy & R. Monderer. 2023. Encyclopedia of Sleep and Circadian Rhythms. Encyclopedia of Sleep and Circadian Rhythms
174
180
.
Habibolah Khazaie, Masoud Sadeghi, Sepideh Khazaie, Max Hirshkowitz & Amir Sharafkhaneh. (2022) Dual orexin receptor antagonists for treatment of insomnia: A systematic review and meta-analysis on randomized, double-blind, placebo-controlled trials of suvorexant and lemborexant. Frontiers in Psychiatry 13.
Crossref
Crossref
Carlos Carrera-Cañas, Isabel de Andrés, Marta Callejo & Miguel Garzón. (2022) Plasticity of the hypocretinergic/orexinergic system after a chronic treatment with suvorexant in rats. Role of the hypocretinergic/orexinergic receptor 1 as an autoreceptor. Frontiers in Molecular Neuroscience 15.
Crossref
Crossref
Kazumaro Okino, Hirohisa Suzuki, Seiji Kondo, Hiroi Tomioka, Takahiro Tokumasu, Hiroki Yamada, Akira Iwanami & Atsuko Inamoto. (2022) Effectiveness of change from suvorexant to lemborexant drug in the treatment of sleep disorders. Psychogeriatrics 22:5, pages 595-604.
Crossref
Crossref
Ping Bai, Yan Liu, Yulong Xu, Robin Striar, Gengyang Yuan, Sepideh Afshar, Amelia G. Langan, Anna K. Rattray & Changning Wang. (2022) Synthesis and characterization of a new Positron emission tomography probe for orexin 2 receptors neuroimaging. Bioorganic Chemistry 123, pages 105779.
Crossref
Crossref
KOTARO HATTA. (2022) Prevention of Delirium Via Melatonin and Orexin Neurotransmission. Juntendo Medical Journal 68:1, pages 12-16.
Crossref
Crossref
Safoor Fathima, Sireesha Murala & Pradeep C. Bollu. 2022. Neurochemistry in Clinical Practice. Neurochemistry in Clinical Practice
181
209
.
Lois E. Krahn, Donna L. Arand, Alon Y. Avidan, David G. Davila, William A. DeBassio, Chad M. Ruoff & Christopher G. Harrod. (2021) Recommended protocols for the Multiple Sleep Latency Test and Maintenance of Wakefulness Test in adults: guidance from the American Academy of Sleep Medicine. Journal of Clinical Sleep Medicine 17:12, pages 2489-2498.
Crossref
Crossref
Sachin Kumar, Tapan Behl, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Saurabh Bhatia, Ahmed Al-Harassi, Mohammed M. Abdel-Daim & Simona Bungau. (2021) Exploring the Role of Orexinergic Neurons in Parkinson’s Disease. Neurotoxicity Research 39:6, pages 2141-2153.
Crossref
Crossref
Lin Xu, Ashok Krishna, Sharron Stewart, Katherine Shea, Rebecca Racz, James L. Weaver, Donna A. Volpe, Nageswara R. Pilli, Suresh Narayanasamy, Jeffry Florian, Vikram Patel, Murali K. Matta, Marc B. Stone, Hao Zhu, Michael C. Davis, David G. Strauss & Rodney Rouse. (2021) Effects of sedative psychotropic drugs combined with oxycodone on respiratory depression in the rat. Clinical and Translational Science 14:6, pages 2208-2219.
Crossref
Crossref
Jacqueline B. Mehr, Deborah Mitchison, Hannah E. Bowrey & Morgan H. James. (2021) Sleep dysregulation in binge eating disorder and “food addiction”: the orexin (hypocretin) system as a potential neurobiological link. Neuropsychopharmacology 46:12, pages 2051-2061.
Crossref
Crossref
Lais F. Berro, Eliseu da Cruz Moreira-Junior & James K. Rowlett. (2021) The dual orexin receptor antagonist almorexant blocks the sleep-disrupting and daytime stimulant effects of methamphetamine in rhesus monkeys. Drug and Alcohol Dependence 227, pages 108930.
Crossref
Crossref
Idris A. Azeez, Olumayowa O. Igado & James O. Olopade. (2021) An overview of the orexinergic system in different animal species. Metabolic Brain Disease 36:7, pages 1419-1444.
Crossref
Crossref
Muneto Izuhara, Shoko Miura, Koji Otsuki, Michiharu Nagahama, Maiko Hayashida, Sadayuki Hashioka, Hiroya Asou, Hajime Kitagaki & Masatoshi Inagaki. (2021) Magnetic Resonance Spectroscopy in the Ventral Tegmental Area Distinguishes Responders to Suvorexant Prior to Treatment: A 4-Week Prospective Cohort Study. Frontiers in Psychiatry 12.
Crossref
Crossref
Mahesh K Kaushik, Kosuke Aritake, Yoan Cherasse, Aya Imanishi, Takashi Kanbayashi, Yoshihiro Urade & Masashi Yanagisawa. (2021) Induction of narcolepsy-like symptoms by orexin receptor antagonists in mice. Sleep 44:8.
Crossref
Crossref
Hiroki Tateishi, Daisuke Miyazu, Hirokazu Tanaka & Masaaki Hirakawa. (2021) Investigation of Potential Drug-Drug Interactions in Rehabilitation Ward Using Lexicomp Drug InteractionsLexicomp Drug Interactionsを用いたリハビリテーション病棟における潜在的な薬物相互作用の調査. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 47:8, pages 397-404.
Crossref
Crossref
Fei Liu, Shengyong Zhao, Linpo Yu & Haibiao Liu. (2021) Condition Optimization for Synthesis of 5-methyl-2(pyrimidin-2-yl) Benzoic Acid. Letters in Organic Chemistry 18:7, pages 501-506.
Crossref
Crossref
Theresa E. Bjorness & Robert W. Greene. (2021) Interaction between cocaine use and sleep behavior: A comprehensive review of cocaine's disrupting influence on sleep behavior and sleep disruptions influence on reward seeking. Pharmacology Biochemistry and Behavior 206, pages 173194.
Crossref
Crossref
Dehui Zhang, David A. Perrey, Ann M. Decker, Tiffany L. Langston, Vijayakumar Mavanji, Danni L. Harris, Catherine M. Kotz & Yanan Zhang. (2021) Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists. Journal of Medicinal Chemistry 64:12, pages 8806-8825.
Crossref
Crossref
Mackenzie C. Gamble, Fumi Katsuki, John G. McCoy, Robert E. Strecker & James T. McKenna. (2021) The Dual Orexin Receptor Antagonist DORA-22 Improves Mild Stress-induced Sleep Disruption During the Natural Sleep Phase of Nocturnal Rats. Neuroscience 463, pages 30-44.
Crossref
Crossref
Jennaya Christensen, Glenn R. Yamakawa, Sandy R. Shultz & Richelle Mychasiuk. (2021) Is the glymphatic system the missing link between sleep impairments and neurological disorders? Examining the implications and uncertainties. Progress in Neurobiology 198, pages 101917.
Crossref
Crossref
Hannah B. Elam, Stephanie M. Perez, Jennifer J. Donegan & Daniel J. Lodge. (2021) Orexin receptor antagonists reverse aberrant dopamine neuron activity and related behaviors in a rodent model of stress-induced psychosis. Translational Psychiatry 11:1.
Crossref
Crossref
Santosh Kumar Prajapati & Sairam Krishnamurthy. (2021) Non-selective orexin-receptor antagonist attenuates stress-re-stress-induced core PTSD-like symptoms in rats: Behavioural and neurochemical analyses. Behavioural Brain Research 399, pages 113015.
Crossref
Crossref
Chiaki Kamei. (2021) Effects of Histamine and Related Compounds on the Central Nervous Systemヒスタミン並びに関連化合物の中枢神経機能に対する効果. YAKUGAKU ZASSHI 141:1, pages 93-110.
Crossref
Crossref
Benjamin E. Blass. 2021. Basic Principles of Drug Discovery and Development. Basic Principles of Drug Discovery and Development
523
560
.
Aditi Banerjee, Trina Sengupta & Hruda Nanda Mallick. (2020) Inhibition of Orexin-1/2 Receptors Disrupts Goal-Oriented Locomotor Activity During Motivated Behaviour in Male Rats. Sleep and Vigilance 4:2, pages 153-159.
Crossref
Crossref
Filipa Rijo-Ferreira, Theresa E. Bjorness, Kimberly H. Cox, Alex Sonneborn, Robert W. Greene & Joseph S. Takahashi. (2020) Sleeping Sickness Disrupts the Sleep-Regulating Adenosine System. The Journal of Neuroscience 40:48, pages 9306-9316.
Crossref
Crossref
Masako Oda, Yurie Furuto, Yuichi Ichimura, Michi Mori, Mari Takahashi & Hiroshi Saitoh. (2020) Stability of Suvorexant (Belsomra<sup>®</sup>) Tablets in One-Dose Packageスボレキサント（ベルソムラ<sup>®</sup>）錠の一包化調剤における安定性の検討. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 46:10, pages 606-612.
Crossref
Crossref
Eva Mezeiova, Jana Janockova, Jan Konecny, Tereza Kobrlova, Marketa Benkova, Rafael Dolezal, Lukas Prchal, Jana Karasova-Zdarova, Ondrej Soukup & Jan Korabecny. (2020) From orexin receptor agonist YNT-185 to novel antagonists with drug-like properties for the treatment of insomnia. Bioorganic Chemistry 103, pages 104179.
Crossref
Crossref
N. Ishibashi-Kanno, S. Takaoka, H. Nagai, M. Okubo-Sato, S. Fukuzawa, F. Uchida, K. Yamagata, T. Yanagawa & H. Bukawa. (2020) Postoperative delirium after reconstructive surgery for oral tumor: a retrospective clinical study. International Journal of Oral and Maxillofacial Surgery 49:9, pages 1143-1148.
Crossref
Crossref
Carrie E Mahoney, Takatoshi Mochizuki & Thomas E Scammell. (2020) Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice. Sleep 43:6.
Crossref
Crossref
Kana Fukasawa, Tsukasa Sekimoto, Kyohei Kaneko & Akinori Takagi. (2020) Effects of Sleeping Medication Switching on Falls and the Risk Assessment According to Functional Mechanism in Chronic Hospitals慢性期病院における転倒・転落に与える睡眠薬切り替えの効果と作用機序別リスク評価. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 46:6, pages 323-330.
Crossref
Crossref
Vladimir Svetnik, Ting-Chuan Wang, Yuting Xu, Bryan J. Hansen & Steven V. Fox. (2020) A Deep Learning Approach for Automated Sleep-Wake Scoring in Pre-Clinical Animal Models. Journal of Neuroscience Methods 337, pages 108668.
Crossref
Crossref
Ying Han, Kai Yuan, Yongbo Zheng & Lin Lu. (2019) Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders. Neuroscience Bulletin 36:4, pages 432-448.
Crossref
Crossref
Masami Yamaguchi, Manabu Ishikawa, Yuri Aono & Tadashi Saigusa. (2019)
OX
2
receptors mediate the inhibitory effects of orexin‐A on potassium chloride‐induced increases in intracellular calcium ion levels in neurons derived from rat dorsal root ganglion in a chronic pain model
. Neuropsychopharmacology Reports 40:1, pages 30-38.
Crossref
Crossref
W. Joseph Herring, Paulette Ceesay, Ellen Snyder, Donald Bliwise, Kerry Budd, Jill Hutzelmann, Joanne Stevens, Christopher Lines & David Michelson. (2020) Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial. Alzheimer's & Dementia 16:3, pages 541-551.
Crossref
Crossref
Mathieu RappasAmmar A. E. AliKirstie A. BennettJason D. BrownSarah J. BucknellMiles Congreve, Robert M. CookeGabriella CsekeChris de GraafAndrew S. DoréJames C. ErreyAli JazayeriFiona H. MarshallJonathan S. MasonRichard MouldJayesh C. PatelBenjamin G. TehanMalcolm WeirJohn A. Christopher. (2019) Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis. Journal of Medicinal Chemistry 63:4, pages 1528-1543.
Crossref
Crossref
Jason M. Uslaner, William J. Herring & Paul J. Coleman. (2020) The Discovery of Suvorexant: Lessons Learned That Can Be Applied to Other CNS Drug Development Efforts. ACS Pharmacology & Translational Science 3:1, pages 161-168.
Crossref
Crossref
Daniel Hoyer, Andrew Allen & Laura H. Jacobson. (2020) Hypnotics with novel modes of action. British Journal of Clinical Pharmacology 86:2, pages 244-249.
Crossref
Crossref
Hiroki Murai, Hiroto Suzuki, Hirochi Tanji, Tomoki Kimura & Yoshinori Iba. (2020) A simple method using anesthetics to test effects of sleep-inducing substances in mice. Journal of Pharmacological Sciences 142:2, pages 79-82.
Crossref
Crossref
Shu Xu, Yuanyuan Cui, Jinhua Shen & Peili Wang. (2020) Suvorexant for the prevention of delirium. Medicine 99:30, pages e21043.
Crossref
Crossref
Tristan Martin, Yves Dauvilliers, Ouma-Chandrou Koumar, Valentine Bouet, Thomas Freret, Stéphane Besnard, François Dauphin & Nicolas Bessot. (2019) Dual orexin receptor antagonist induces changes in core body temperature in rats after exercise. Scientific Reports 9:1.
Crossref
Crossref
Jaehoon SeolYuya FujiiInsung ParkYoko SuzukiFusae KawanaKatsuhiko YajimaShoji FukusumiTomohiro OkuraMakoto SatohKumpei TokuyamaToshio KokuboMasashi Yanagisawa. (2019)
Distinct effects of orexin receptor antagonist and GABA
A
agonist on sleep and physical/cognitive functions after forced awakening
. Proceedings of the National Academy of Sciences 116:48, pages 24353-24358.
Crossref
Crossref
Mackenzie C Gamble, Fumi Katsuki, John G McCoy, Robert E Strecker & James Timothy McKenna. (2019) The dual orexinergic receptor antagonist DORA-22 improves the sleep disruption and memory impairment produced by a rodent insomnia model. Sleep.
Crossref
Crossref
Carsten Theodor Beuckmann, Takashi Ueno, Makoto Nakagawa, Michiyuki Suzuki & Shigeru Akasofu. (2019) Preclinical in vivo characterization of lemborexant (E2006), a novel dual orexin receptor antagonist for sleep/wake regulation. Sleep 42:6.
Crossref
Crossref
Aisha S. Shariq, Joshua D. Rosenblat, Asem Alageel, Rodrigo B. Mansur, Carola Rong, Roger C. Ho, Renee-Marie Ragguett, Zihang Pan, Elisa Brietzke & Roger S. McIntyre. (2019) Evaluating the role of orexins in the pathophysiology and treatment of depression: A comprehensive review. Progress in Neuro-Psychopharmacology and Biological Psychiatry 92, pages 1-7.
Crossref
Crossref
Ainoleena Turku, Teppo O. Leino, Lasse Karhu, Jari Yli‐Kauhaluoma, Jyrki P. Kukkonen, Erik A. A. Wallén & Henri Xhaard. (2019)
Structure–Activity Relationships of 1‐Benzoylazulenes at the OX
1
and OX
2
Orexin Receptors
. ChemMedChem 14:9, pages 965-981.
Crossref
Crossref
W. Joseph Herring, Thomas Roth, Andrew D. Krystal & David Michelson. (2018) Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications. Journal of Sleep Research 28:2.
Crossref
Crossref
Manuel Sanchez-Alavez, Jessica Benedict, Derek N Wills & Cindy L Ehlers. (2019) Effect of suvorexant on event-related oscillations and EEG sleep in rats exposed to chronic intermittent ethanol vapor and protracted withdrawal. Sleep 42:4.
Crossref
Crossref
W. Joseph Herring, Kathryn M. Connor, Ellen Snyder, Duane B. Snavely, Charles M. Morin, Christopher Lines & David Michelson. (2019) Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data. Sleep Medicine 56, pages 219-223.
Crossref
Crossref
Motahareh Rouhi Ardeshiri, Narges Hosseinmardi & Esmaeil Akbari. (2019) The basolateral amygdala orexin 1 and 2 receptors’ involvement in modulating spatial reference memory. Brain Research 1704, pages 16-25.
Crossref
Crossref
Kei Kawada, Tsuyoshi Ohta, Koudai Tanaka, Mitsuhiko Miyamura & Satoshi Tanaka. (2019) Addition of Suvorexant to Ramelteon Therapy for Improved Sleep Quality with Reduced Delirium Risk in Acute Stroke Patients. Journal of Stroke and Cerebrovascular Diseases 28:1, pages 142-148.
Crossref
Crossref
Claudio Perez-Leighton, Jennifer A. Teske & Catherine M. Kotz. 2019. The Orexin/Hypocretin System. The Orexin/Hypocretin System
69
84
.
Kimberly J. Jennings & Luis de Lecea. 2019. The Orexin/Hypocretin System. The Orexin/Hypocretin System
1
29
.
David N. Neubauer. 2019. Handbook of Sleep Research. Handbook of Sleep Research
639
648
.
Joanne Stevens & Carrie Markgraf. 2019. Advanced Issue Resolution in Safety Pharmacology. Advanced Issue Resolution in Safety Pharmacology
103
129
.
Andrea Lawson, Roohie Parmar & Eileen P. Sloan. 2019. Perinatal Psychopharmacology. Perinatal Psychopharmacology
341
376
.
Jana Janockova, Rafael Dolezal, Eugenie Nepovimova, Tereza Kobrlova, Marketa Benkova, Kamil Kuca, Jan Konecny, Eva Mezeiova, Michaela Melikova, Vendula Hepnarova, Avi Ring, Ondrej Soukup & Jan Korabecny. (2018) Investigation of New Orexin 2 Receptor Modulators Using In Silico and In Vitro Methods. Molecules 23:11, pages 2926.
Crossref
Crossref
Clemens Muehlan, Jules Heuberger, Pierre-Eric Juif, Marie Croft, Joop van Gerven & Jasper Dingemanse. (2018) Accelerated Development of the Dual Orexin Receptor Antagonist ACT-541468: Integration of a Microtracer in a First-in-Human Study. Clinical Pharmacology & Therapeutics 104:5, pages 1022-1029.
Crossref
Crossref
Shi-Bin Li, Natalie Nevárez, William J Giardino & Luis de Lecea. (2018) Optical probing of orexin/hypocretin receptor antagonists. Sleep 41:10.
Crossref
Crossref
Qifeng Bai, Horacio Pérez-Sánchez, Zhuoyu Shi, Lanlan Li, Danfeng Shi, Huanxiang Liu & Xiaojun Yao. (2018) Computational studies on horseshoe shape pocket of human orexin receptor type 2 and boat conformation of suvorexant by molecular dynamics simulations. Chemical Biology & Drug Design 92:1, pages 1221-1231.
Crossref
Crossref
Ka Lai Yee, Jacqueline McCrea, Deborah Panebianco, Wen Liu, Nicole Lewis, Tamara Cabalu, Steven Ramael & Rebecca E. Wrishko. (2018) Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men. Clinical Drug Investigation 38:7, pages 631-638.
Crossref
Crossref
Chunmei Wang, Qinqin Wang, Bingyuan Ji, Yanyou Pan, Chao Xu, Baohua Cheng, Bo Bai & Jing Chen. (2018) The Orexin/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases. Frontiers in Molecular Neuroscience 11.
Crossref
Crossref
Zhen Cai, Hehe Liu, Liyun Wang, Xinxin Li, Lili Bai, Xinmeng Gan, Liang Li & Chunchun Han. (2018) Molecular Evolutionary Analysis of the HCRTR Gene Family in Vertebrates. BioMed Research International 2018, pages 1-9.
Crossref
Crossref
Tobias Atkin, Stefano Comai & Gabriella Gobbi. (2018) Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery. Pharmacological Reviews 70:2, pages 197-245.
Crossref
Crossref
E. Z. Yakupov, D. V. Artemieva & Yu. V. Troshina. (2018) Multimodality of clinical effects of orexin. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 118:12, pages 114.
Crossref
Crossref
Taylor A. Gentile, Steven J. Simmons, David J. Barker, Jessica K. Shaw, Rodrigo A. España & John W. Muschamp. (2018) Suvorexant, an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine. Addiction Biology 23:1, pages 247-255.
Crossref
Crossref
Vladimir Svetnik, Ellen S Snyder, Peining Tao, Thomas E Scammell, Thomas Roth, Christopher Lines & W Joseph Herring. (2018) Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts. Sleep 41:1.
Crossref
Crossref
David N. Neubauer & Sapna R. Kudchadkar. (2017) Impatient for Inpatient Sleep: Treating Sleep Disturbances in the Hospital Setting. Current Sleep Medicine Reports 3:4, pages 333-341.
Crossref
Crossref
Young-Jin KangGuilian TianAfsheen BazrafkanMaryam H. FarahabadiMatine AzadianHamidreza AbbasiBrittany E. ShamaounOswald StewardYama Akbari. (2017) Recovery from Coma Post-Cardiac Arrest Is Dependent on the Orexin Pathway. Journal of Neurotrauma 34:19, pages 2823-2832.
Crossref
Crossref
Hidenobu Suzuki, Hiroyuki Hibino, Yuichi Inoue, Ayako Mikami, Hideo Matsumoto & Katsunaka Mikami. (2017) Benefits associated with switching from benzodiazepine hypnotics to suvorexant in patients with mild primary insomnia. Asian Journal of Psychiatry 29, pages 71-72.
Crossref
Crossref
Yoshihiro Urade. (2017) Neurobiological Basis of Hypersomnia. Sleep Medicine Clinics 12:3, pages 265-277.
Crossref
Crossref
Carsten Theodor Beuckmann, Michiyuki Suzuki, Takashi Ueno, Kazuya Nagaoka, Tohru Arai & Hiroyuki Higashiyama. (2017) In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist. Journal of Pharmacology and Experimental Therapeutics 362:2, pages 287-295.
Crossref
Crossref
Hidenobu Suzuki, Hiroyuki Hibino, Yuichi Inoue, Ayako Mikami, Hideo Matsumoto & Katsunaka Mikami. (2017) Reduced insomnia following short-term administration of suvorexant during aripiprazole once-monthly treatment in a patient with schizophrenia. Asian Journal of Psychiatry 28, pages 165-166.
Crossref
Crossref
Lihang Yao, Andres D. Ramirez, Anthony J. Roecker, Steven V. Fox, Jason M. Uslaner, Sean M. Smith, Robert Hodgson, Paul J. Coleman, John J. Renger, Christopher J. Winrow & Anthony L. Gotter. (2017) The dual orexin receptor antagonist, DORA-22, lowers histamine levels in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine. Journal of Neurochemistry 142:2, pages 204-214.
Crossref
Crossref
W. Joseph Herring, Kathryn M. Connor, Ellen Snyder, Duane B. Snavely, Ying Zhang, Jill Hutzelmann, Deborah Matzura-Wolfe, Ruth M. Benca, Andrew D. Krystal, James K. Walsh, Christopher Lines, Thomas Roth & David Michelson. (2017) Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials. The American Journal of Geriatric Psychiatry 25:7, pages 791-802.
Crossref
Crossref
Eisuke Booka, Yasuhiro Tsubosa, Teruaki Matsumoto, Mari Takeuchi, Takashi Kitani, Masato Nagaoka, Atsushi Imai, Tomoyuki Kamijo, Yoshiyuki Iida, Ayako Shimada, Katsushi Takebayashi, Masahiro Niihara, Keita Mori, Tetsuro Onitsuka, Hiroya Takeuchi & Yuko Kitagawa. (2017) Postoperative delirium after pharyngolaryngectomy with esophagectomy: a role for ramelteon and suvorexant. Esophagus 14:3, pages 229-234.
Crossref
Crossref
Stephanie Born, David V. Gauvin, Suman Mukherjee & Richard Briscoe. (2017) Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant. Regulatory Toxicology and Pharmacology 86, pages 181-192.
Crossref
Crossref
W. Joseph Herring, Kathryn M. Connor, Ellen Snyder, Duane B. Snavely, Ying Zhang, Jill Hutzelmann, Deborah Matzura-Wolfe, Ruth M. Benca, Andrew D. Krystal, James K. Walsh, Christopher Lines, Thomas Roth & David Michelson. (2017) Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data. Psychopharmacology 234:11, pages 1703-1711.
Crossref
Crossref
Songliang Wu, Yu Sun, Yi Hu, Hongmei Zhang, Lijuan Hou, Xing Liu, Yufeng Li, Haiying He, Zhi Luo, Yuan Chen, Yuhe Wang, Weihua Shi, Liang Shen, Changqing Cao, Wei Liang, Qing Xu, Qiang Lv, Jiong Lan, Jian Li & Shuhui Chen. (2017) Discovery of novel substituted octahydropyrrolo[3,4- c ]pyrroles as dual orexin receptor antagonists for insomnia treatment. Bioorganic & Medicinal Chemistry Letters 27:6, pages 1458-1462.
Crossref
Crossref
Paul J. ColemanAnthony L. Gotter, W. Joseph Herring, Christopher J. Winrow & John J. Renger. (2017) The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia. Annual Review of Pharmacology and Toxicology 57:1, pages 509-533.
Crossref
Crossref
Manabu Ishikawa, Yuri Aono & Tadashi Saigusa. (2017) Role of orexin receptor subtypes in the inhibitory effects of orexin-A on potassium chloride-induced increases in intracellular calcium ion levels in neurons derived from dorsal root ganglion of carrageenan-treated rats. Journal of Oral Science 59:4, pages 557-564.
Crossref
Crossref
Daniel J. Buysse & Shachi Tyagi. 2017. Principles and Practice of Sleep Medicine. Principles and Practice of Sleep Medicine
432
445.e7
.
Thomas S. Kilduff & Wallace B. Mendelson. 2017. Principles and Practice of Sleep Medicine. Principles and Practice of Sleep Medicine
424
431.e5
.
B.T. Shireman & M.A. Letavic. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
225
279
.
Paula K. Schweitzer & Stephen D. Feren. 2017. Clinical Handbook of Insomnia. Clinical Handbook of Insomnia
97
132
.
Max Hirshkowitz & Hanul Bhandari. 2017. Sleep Disorders Medicine. Sleep Disorders Medicine
103
118
.
Arie Struyk, Cynthia Gargano, Melissa Drexel, S. Aubrey Stoch, Vladimir Svetnik, Junshui Ma & David Mayleben. (2016) Pharmacodynamic effects of suvorexant and zolpidem on EEG during sleep in healthy subjects. European Neuropsychopharmacology 26:10, pages 1649-1656.
Crossref
Crossref
Simon Authier, Marcus S. Delatte, Mary-Jeanne Kallman, Joanne Stevens & Carrie Markgraf. (2016) EEG in non-clinical drug safety assessments: Current and emerging considerations. Journal of Pharmacological and Toxicological Methods 81, pages 274-285.
Crossref
Crossref
Hiroshi Tsuneki, Toshiyasu Sasaoka & Takeshi Sakurai. (2016) Sleep Control, GPCRs, and Glucose Metabolism. Trends in Endocrinology & Metabolism 27:9, pages 633-642.
Crossref
Crossref
Kerri A. SchoedelHong SunEdward M. SellersJanice FaulknorNaama Levy-CoopermanXiaodong LiWilliam P. KennedyJang-Ho ChaNicole M. LewisWen LiuPhung BondiskeyJacqueline B. McCreaDeborah L. PanebiancoMatthew D. TroyerJohn A. Wagner. (2016) Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study. Journal of Clinical Psychopharmacology 36:4, pages 314-323.
Crossref
Crossref
Kathryn M. Connor, Erin Mahoney, Saheeda Jackson, Jill Hutzelmann, Xin Zhao, Nan Jia, Ellen Snyder, Duane Snavely, David Michelson, Thomas Roth & W. Joseph Herring. (2016) A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia. International Journal of Neuropsychopharmacology 19:8, pages pyw022.
Crossref
Crossref
Anthony L. Gotter, Mark S. Forman, Charles M. Harrell, Joanne Stevens, Vladimir Svetnik, Ka Lai Yee, Xiaodong Li, Anthony J. Roecker, Steven V. Fox, Pamela L. Tannenbaum, Susan L. Garson, Inge De Lepeleire, Nicole Calder, Laura Rosen, Arie Struyk, Paul J. Coleman, W. Joseph Herring, John J. Renger & Christopher J. Winrow. (2016) Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man. Scientific Reports 6:1.
Crossref
Crossref
Anil Kumar, Priyanka Chanana & Supriti Choudhary. (2016) Emerging role of orexin antagonists in insomnia therapeutics: An update on SORAs and DORAs. Pharmacological Reports 68:2, pages 231-242.
Crossref
Crossref
Pamela L. Tannenbaum, Spencer J. Tye, Joanne Stevens, Anthony L. Gotter, Steven V. Fox, Alan T. Savitz, Paul J. Coleman, Jason M. Uslaner, Scott D. Kuduk, Richard Hargreaves, Christopher J. Winrow & John J. Renger. (2016) Inhibition of Orexin Signaling Promotes Sleep Yet Preserves Salient Arousability in Monkeys. Sleep 39:3, pages 603-612.
Crossref
Crossref
Gregory S Parks, Deepti R Warrier, Lars Dittrich, Michael D Schwartz, Jeremiah B Palmerston, Thomas C Neylan, Stephen R Morairty & Thomas S Kilduff. (2015) The Dual Hypocretin Receptor Antagonist Almorexant is Permissive for Activation of Wake-Promoting Systems. Neuropsychopharmacology 41:4, pages 1144-1155.
Crossref
Crossref
Ellen Snyder, Junshui Ma, Vladimir Svetnik, Kathryn M. Connor, Christopher Lines, David Michelson & W. Joseph Herring. (2016) Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: analysis of pooled phase 3 data. Sleep Medicine 19, pages 93-100.
Crossref
Crossref
Jacqueline Vazquez-DeRose, Michael D. Schwartz, Alexander T. Nguyen, Deepti R. Warrier, Srishti Gulati, Thomas K. Mathew, Thomas C. Neylan & Thomas S. Kilduff. (2014) Hypocretin/orexin antagonism enhances sleep-related adenosine and GABA neurotransmission in rat basal forebrain. Brain Structure and Function 221:2, pages 923-940.
Crossref
Crossref
Anthony J. Roecker, Christopher D. Cox & Paul J. Coleman. (2015) Orexin Receptor Antagonists: New Therapeutic Agents for the Treatment of Insomnia. Journal of Medicinal Chemistry 59:2, pages 504-530.
Crossref
Crossref
Yoshitaka Tanaka, Ikuo Aoki, Takaaki Ishine, John J. Renger, Christopher J. Winrow & Satoru Hisada. (2016) Preclinical and clinical results of dual orexin receptor antagonist, suvorexant (BELSOMRA<sup>®</sup>), a novel therapeutic agent for insomnia. Folia Pharmacologica Japonica 148:1, pages 46-56.
Crossref
Crossref
Debra J. Wallace, Ian Mangion & Paul Coleman. 2016. Comprehensive Accounts of Pharmaceutical Research and Development: From Discovery to Late-Stage Process Development Volume 1. Comprehensive Accounts of Pharmaceutical Research and Development: From Discovery to Late-Stage Process Development Volume 1
1
36
.
W. Joseph Herring, Kathryn M. Connor, Neely Ivgy-May, Ellen Snyder, Ken Liu, Duane B. Snavely, Andrew D. Krystal, James K. Walsh, Ruth M. Benca, Russell Rosenberg, R. Bart Sangal, Kerry Budd, Jill Hutzelmann, Heather Leibensperger, Samar Froman, Christopher Lines, Thomas Roth & David Michelson. (2016) Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials. Biological Psychiatry 79:2, pages 136-148.
Crossref
Crossref
Laura H. Jacobson, Sui Chen, Sanjida Mir & Daniel Hoyer. 2017. Behavioral Neuroscience of Orexin/Hypocretin. Behavioral Neuroscience of Orexin/Hypocretin
105
136
.
Michael D. Schwartz & Thomas S. Kilduff. (2015) The Neurobiology of Sleep and Wakefulness. Psychiatric Clinics of North America 38:4, pages 615-644.
Crossref
Crossref
Dirk Behnke, Simona Cotesta, Samuel Hintermann, Markus Fendt, Christine E. Gee, Laura H. Jacobson, Grit Laue, Arndt Meyer, Trixie Wagner, Sangamesh Badiger, Vinod Chaudhari, Murali Chebrolu, Chetan Pandit, Daniel Hoyer & Claudia Betschart. (2015) Discovery of 1 H -pyrazolo[3,4- b ]pyridines as potent dual orexin receptor antagonists (DORAs). Bioorganic & Medicinal Chemistry Letters 25:23, pages 5555-5560.
Crossref
Crossref
Nadia M. Ahmad. 2015. Innovative Drug Synthesis. Innovative Drug Synthesis
223
242
.
Annemiek Vermeeren, Hong Sun, Eric F.P.M. Vuurman, Stefan Jongen, Cees J. Van Leeuwen, Anita C.M. Van Oers, John Palcza, Xiadong Li, Tine Laethem, Ingeborg Heirman, An Bautmans, Matthew D. Troyer, Rebecca Wrishko & Jacqueline McCrea. (2015) On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers. Sleep 38:11, pages 1803-1813.
Crossref
Crossref
Hong Sun, Ka Lai Yee, Sean Gill, Wen Liu, Xiaodong Li, Deborah Panebianco, Eric Mangin, Dennis Morrison, Jacqueline McCrea, John A Wagner & Matthew D Troyer. (2015) Psychomotor effects, pharmacokinetics and safety of the orexin receptor antagonist suvorexant administered in combination with alcohol in healthy subjects. Journal of Psychopharmacology 29:11, pages 1159-1169.
Crossref
Crossref
Anthony J. Roecker, Swati P. Mercer, Jeffrey M. Bergman, Kevin F. Gilbert, Scott D. Kuduk, C. Meacham Harrell, Susan L. Garson, Steven V. Fox, Anthony L. Gotter, Pamela L. Tannenbaum, Thomayant Prueksaritanont, Tamara D. Cabalu, Donghui Cui, Wei Lemaire, Christopher J. Winrow, John J. Renger & Paul J. Coleman. (2015) Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements. Bioorganic & Medicinal Chemistry Letters 25:21, pages 4992-4999.
Crossref
Crossref
Takashi Nagahara, Tsuyoshi Saitoh, Noriki Kutsumura, Yoko Irukayama-Tomobe, Yasuhiro Ogawa, Daisuke Kuroda, Hiroaki Gouda, Hidetoshi Kumagai, Hideaki Fujii, Masashi Yanagisawa & Hiroshi Nagase. (2015) Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists. Journal of Medicinal Chemistry 58:20, pages 7931-7937.
Crossref
Crossref
S.A. Breidinger, R.C. Simpson, E. Mangin & E.J. Woolf. (2015) Determination of suvorexant in human plasma using 96-well liquid–liquid extraction and HPLC with tandem mass spectrometric detection. Journal of Chromatography B 1002, pages 254-259.
Crossref
Crossref
Naoto Uemura, Jacqueline McCrea, Hong Sun, Mardik Donikyan, Gary Zammit, Rong Liu, Bonnie Louridas, Sabrina Marsilio, Christopher Lines, Matthew D. Troyer & John Wagner. (2015) Effects of the orexin receptor antagonist suvorexant on respiration during sleep in healthy subjects. The Journal of Clinical Pharmacology 55:10, pages 1093-1100.
Crossref
Crossref
Vijayakumar Mavanji, Claudio E. Perez-Leighton, Catherine M. Kotz, Charles J. Billington, Sairam Parthasarathy, Christopher M. Sinton & Jennifer A. Teske. (2015) Promotion of Wakefulness and Energy Expenditure by Orexin-A in the Ventrolateral Preoptic Area. Sleep 38:9, pages 1361-1370.
Crossref
Crossref
Yu Yoshida, Yoshimitsu Naoe, Taro Terauchi, Fumihiro Ozaki, Takashi Doko, Ayumi Takemura, Toshiaki Tanaka, Keiichi Sorimachi, Carsten T. Beuckmann, Michiyuki Suzuki, Takashi Ueno, Shunsuke Ozaki & Masahiro Yonaga. (2015)
Discovery of (1
R
,2
S
)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-
N
-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist
. Journal of Medicinal Chemistry 58:11, pages 4648-4664.
Crossref
Crossref
Scott D. Kuduk, Jason W. Skudlarek, Christina N. DiMarco, Joseph G. Bruno, Mark H. Pausch, Julie A. O’Brien, Tamara D. Cabalu, Joanne Stevens, Joseph Brunner, Pamela L. Tannenbaum, Susan L. Garson, Alan T. Savitz, Charles M. Harrell, Anthony L. Gotter, Christopher J. Winrow, John J. Renger & Paul J. Coleman. (2015) Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties. Bioorganic & Medicinal Chemistry Letters 25:12, pages 2488-2492.
Crossref
Crossref
Daniele Viviani, Patrizia Haegler, Francois Jenck & Michel A. Steiner. (2014) Orexin neuropeptides contribute to the development and persistence of generalized avoidance behavior in the rat. Psychopharmacology 232:8, pages 1383-1393.
Crossref
Crossref
Hong Sun, John Palcza, Russell Rosenberg, Meir Kryger, Tara Siringhaus, Janice Rowe, Christopher Lines, John A. Wagner & Matthew D. Troyer. (2015) Effects of suvorexant, an orexin receptor antagonist, on breathing during sleep in patients with chronic obstructive pulmonary disease. Respiratory Medicine 109:3, pages 416-426.
Crossref
Crossref
Siamak Sorooshyari, Ramón Huerta & Luis de Lecea. (2015) A Framework for Quantitative Modeling of Neural Circuits Involved in Sleep-to-Wake Transition. Frontiers in Neurology 6.
Crossref
Crossref
Abhishek Reddy, Sowmya C Puvvada, Satyanarayana Kommisetti, Rif S. El-Mallakh & Steven Lippmann. (2014) Suvorexant: something new for sleep?. Acta Neuropsychiatrica 27:1, pages 53-55.
Crossref
Crossref
Izzat T. Raheem, Michael J. Breslin, Joseph Bruno, Tamara D. Cabalu, Andrew Cooke, Christopher D. Cox, Donghui Cui, Susan Garson, Anthony L. Gotter, Steven V. Fox, C. Meacham Harrell, Scott D. Kuduk, Wei Lemaire, Thomayant Prueksaritanont, John J. Renger, Craig Stump, Pamela L. Tannenbaum, Peter D. Williams, Christopher J. Winrow & Paul J. Coleman. (2015) Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant. Bioorganic & Medicinal Chemistry Letters 25:3, pages 444-450.
Crossref
Crossref
Dennis J. Cada, Terri L. Levien & Danial E. Baker. (2015) Suvorexant. Hospital Pharmacy 50:1, pages 059-074.
Crossref
Crossref
Dennis Cada, Terri Levien & Danial Baker. (2015) Suvorexant. Hospital Pharmacy 50:1, pages 059-071.
Crossref
Crossref
Benjamin E. Blass. 2015. Basic Principles of Drug Discovery and Development. Basic Principles of Drug Discovery and Development
415
446
.
Jason M. Uslaner, John J. Renger, Paul J. Coleman & Chris J. Winrow. 2015. Orexin and Sleep. Orexin and Sleep
323
338
.
Vivien C. Abad & Christian Guilleminault. 2015. Sleep, Neuronal Plasticity and Brain Function. Sleep, Neuronal Plasticity and Brain Function
503
553
.
Quanhui Chen, Luis de Lecea, Zhian Hu & Dong Gao. (2015) The Hypocretin/Orexin System: An Increasingly Important Role in Neuropsychiatry. Medicinal Research Reviews 35:1, pages 152-197.
Crossref
Crossref
Anthony L Gotter, Susan L Garson, Joanne Stevens, Regina L Munden, Steven V Fox, Pamela L Tannenbaum, Lihang Yao, Scott D Kuduk, Terrence McDonald, Jason M Uslaner, Spencer J Tye, Paul J Coleman, Christopher J Winrow & John J Renger. (2014) Differential sleep-promoting effects of dual orexin receptor antagonists and GABAAreceptor modulators. BMC Neuroscience 15:1.
Crossref
Crossref
Yu Yoshida, Taro Terauchi, Yoshimitsu Naoe, Yuji Kazuta, Fumihiro Ozaki, Carsten T. Beuckmann, Makoto Nakagawa, Michiyuki Suzuki, Ikuo Kushida, Osamu Takenaka, Takashi Ueno & Masahiro Yonaga. (2014) Design, synthesis, and structure–activity relationships of a series of novel N-aryl-2-phenylcyclopropanecarboxamide that are potent and orally active orexin receptor antagonists. Bioorganic & Medicinal Chemistry 22:21, pages 6071-6088.
Crossref
Crossref
Junshui Ma, Vladimir Svetnik, Ellen Snyder, Christopher Lines, Thomas Roth & W. Joseph Herring. (2014) Electroencephalographic Power Spectral Density Profile of the Orexin Receptor Antagonist Suvorexant in Patients with Primary Insomnia and Healthy Subjects. Sleep 37:10, pages 1609-1619.
Crossref
Crossref
Lily P. H. Yang. (2014) Suvorexant: First Global Approval. Drugs 74:15, pages 1817-1822.
Crossref
Crossref
Shaun Yon-Seng Khoo & Robyn Mary Brown. (2014) Orexin/Hypocretin Based Pharmacotherapies for the Treatment of Addiction: DORA or SORA?. CNS Drugs 28:8, pages 713-730.
Crossref
Crossref
Pamela L. Tannenbaum, Joanne Stevens, Jacquelyn Binns, Alan T. Savitz, Susan L. Garson, Steven V. Fox, Paul Coleman, Scott D. Kuduk, Anthony L. Gotter, Michael Marino, Spencer J. Tye, Jason M. Uslaner, Christopher J. Winrow & John J. Renger. (2014) Orexin receptor antagonist-induced sleep does not impair the ability to wake in response to emotionally salient acoustic stimuli in dogs. Frontiers in Behavioral Neuroscience 8.
Crossref
Crossref
Miles D. Thompson, Henri Xhaard, Takeshi Sakurai, Innocenzo Rainero & Jyrki P. Kukkonen. (2014) OX1 and OX2 orexin/hypocretin receptor pharmacogenetics. Frontiers in Neuroscience 8.
Crossref
Crossref
Anthony J. Roecker, Swati P. Mercer, C. Meacham Harrell, Susan L. Garson, Steven V. Fox, Anthony L. Gotter, Thomayant Prueksaritanont, Tamara D. Cabalu, Donghui Cui, Wei Lemaire, Christopher J. Winrow, John J. Renger & Paul J. Coleman. (2014) Discovery of dual orexin receptor antagonists with rat sleep efficacy enabled by expansion of the acetonitrile-assisted/diphosgene-mediated 2,4-dichloropyrimidine synthesis. Bioorganic & Medicinal Chemistry Letters 24:9, pages 2079-2085.
Crossref
Crossref
David Michelson, Ellen Snyder, Erin Paradis, Mary Chengan-Liu, Duane B Snavely, Jill Hutzelmann, James K Walsh, Andrew D Krystal, Ruth M Benca, Martin Cohn, Christopher Lines, Thomas Roth & W Joseph Herring. (2014) Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. The Lancet Neurology 13:5, pages 461-471.
Crossref
Crossref
William Vaughn McCallJulieta ScaloKaren Rascati. 2014. Advances in the Management of Primary and Secondary Insomnia. Advances in the Management of Primary and Secondary Insomnia
72
90
.
M. Dresler, V.I. Spoormaker, P. Beitinger, M. Czisch, M. Kimura, A. Steiger & F. Holsboer. (2014) Neuroscience-driven discovery and development of sleep therapeutics. Pharmacology & Therapeutics 141:3, pages 300-334.
Crossref
Crossref
Anthony J. Roecker, Swati P. Mercer, John D. Schreier, Christopher D. Cox, Mark E. Fraley, Justin T. Steen, Wei Lemaire, Joseph G. Bruno, C. Meacham Harrell, Susan L. Garson, Anthony L. Gotter, Steven V. Fox, Joanne Stevens, Pamela L. Tannenbaum, Thomayant Prueksaritanont, Tamara D. Cabalu, Donghui Cui, Joyce Stellabott, George D. Hartman, Steven D. Young, Christopher J. Winrow, John J. Renger & Paul J. Coleman. (2014)
Discovery of 5′′-Chloro-
N
-[(5,6-dimethoxypyridin-2-yl)methyl]-2,2′:5′,3′′-terpyridine-3′-carboxamide (MK-1064): A Selective Orexin 2 Receptor Antagonist (2-SORA) for the Treatment of Insomnia
. ChemMedChem 9:2, pages 311-322.
Crossref
Crossref
Jingcheng Li, Zhian Hu & Luis de Lecea. (2014) The hypocretins/orexins: integrators of multiple physiological functions. British Journal of Pharmacology 171:2, pages 332-350.
Crossref
Crossref
C J Winrow & J J Renger. (2014) Discovery and development of orexin receptor antagonists as therapeutics for insomnia. British Journal of Pharmacology 171:2, pages 283-293.
Crossref
Crossref
Artur Pałasz, Damien Lapray, Christelle Peyron, Ewa Rojczyk-Gołębiewska, Rafał Skowronek, Grzegorz Markowski, Beata Czajkowska, Marek Krzystanek & Ryszard Wiaderkiewicz. (2013) Dual orexin receptor antagonists – promising agents in the treatment of sleep disorders. The International Journal of Neuropsychopharmacology 17:01, pages 157-168.
Crossref
Crossref
J.A. Teske, C.J. Billington & C.M. Kotz. (2014) Mechanisms underlying obesity resistance associated with high spontaneous physical activity. Neuroscience 256, pages 91-100.
Crossref
Crossref
Anthony L Gotter, Christopher J Winrow, Joseph Brunner, Susan L Garson, Steven V Fox, Jacquelyn Binns, Charles M Harrell, Donghui Cui, Ka Lai Yee, Mark Stiteler, Joanne Stevens, Alan Savitz, Pamela L Tannenbaum, Spencer J Tye, Terrence McDonald, Leon Yao, Scott D Kuduk, Jason Uslaner, Paul J Coleman & John J Renger. (2013) The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold. BMC Neuroscience 14:1.
Crossref
Crossref
Daniel Hoyer & Laura H. Jacobson. (2013) Orexin in sleep, addiction and more: Is the perfect insomnia drug at hand?. Neuropeptides 47:6, pages 477-488.
Crossref
Crossref
Swati P. Mercer, Anthony J. Roecker, Susan Garson, Duane R. Reiss, C. Meacham Harrell, Kathy L. Murphy, Joseph G. Bruno, Rodney A. Bednar, Wei Lemaire, Donghui Cui, Tamara D. Cabalu, Cuyue Tang, Thomayant Prueksaritanont, George D. Hartman, Steven D. Young, Christopher J. Winrow, John J. Renger & Paul J. Coleman. (2013) Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs). Bioorganic & Medicinal Chemistry Letters 23:24, pages 6620-6624.
Crossref
Crossref
Steven V Fox, Anthony L Gotter, Spencer J Tye, Susan L Garson, Alan T Savitz, Jason M Uslaner, Joseph I Brunner, Pamela L Tannenbaum, Terrence P McDonald, Robert Hodgson, Lihang Yao, Mark R Bowlby, Scott D Kuduk, Paul J Coleman, Richard Hargreaves, Christopher J Winrow & John J Renger. (2013) Quantitative Electroencephalography Within Sleep/Wake States Differentiates GABAA Modulators Eszopiclone and Zolpidem From Dual Orexin Receptor Antagonists in Rats. Neuropsychopharmacology 38:12, pages 2401-2408.
Crossref
Crossref
Changning Wang, Colin M. Wilson, Christian K. Moseley, Stephen M. Carlin, Shirley Hsu, Grae Arabasz, Frederick A. Schroeder, Christin Y. Sander & Jacob M. Hooker. (2013) Evaluation of potential PET imaging probes for the orexin 2 receptors. Nuclear Medicine and Biology 40:8, pages 1000-1005.
Crossref
Crossref
I. G. Sil’kis. (2013) Possible Mechanisms for the Effects of Orexin on Hippocampal Functioning and Spatial Learning (analytical review). Neuroscience and Behavioral Physiology 43:9, pages 1049-1057.
Crossref
Crossref
Claudia Betschart, Samuel Hintermann, Dirk Behnke, Simona Cotesta, Markus Fendt, Christine E. Gee, Laura H. Jacobson, Grit Laue, Silvio Ofner, Vinod Chaudhari, Sangamesh Badiger, Chetan Pandit, Juergen Wagner & Daniel Hoyer. (2013) Identification of a Novel Series of Orexin Receptor Antagonists with a Distinct Effect on Sleep Architecture for the Treatment of Insomnia. Journal of Medicinal Chemistry 56:19, pages 7590-7607.
Crossref
Crossref
Manas K. Ghorai, Deo Prakash Tiwari & Aditya Bhattacharyya. 2015. Stereoselective Synthesis of Drugs and Natural Products. Stereoselective Synthesis of Drugs and Natural Products
1
38
.
Terry P. Lebold, Pascal Bonaventure & Brock T. Shireman. (2013) Selective orexin receptor antagonists. Bioorganic & Medicinal Chemistry Letters 23:17, pages 4761-4769.
Crossref
Crossref
Norihito Oi, Michiyuki SuzukiTaro TerauchiMasaki TokunagaYosuke Nakatani, Noboru YamamotoToshimitsu FukumuraMing-Rong ZhangTetsuya Suhara & Makoto Higuchi. (2013) Synthesis and Evaluation of Novel Radioligands for Positron Emission Tomography Imaging of the Orexin-2 Receptor. Journal of Medicinal Chemistry 56:16, pages 6371-6385.
Crossref
Crossref
Matthias Hoch, Petra Hoever, Rudolf Theodor & Jasper Dingemanse. (2013) Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin. European Journal of Clinical Pharmacology 69:6, pages 1235-1245.
Crossref
Crossref
Michel A. Steiner, John Gatfield, Catherine Brisbare-Roch, Hendrik Dietrich, Alexander Treiber, Francois Jenck & Christoph Boss. (2013) Discovery and Characterization of ACT-335827, an Orally Available, Brain Penetrant Orexin Receptor Type 1 Selective Antagonist. ChemMedChem 8:6, pages 898-903.
Crossref
Crossref
Jason M. UslanerSpencer J. TyeDonnie M. EddinsXiaohai WangSteven V. FoxAlan T. SavitzJacquelyn BinnsChristopher E. CannonSusan L. GarsonLihang YaoRobert HodgsonJoanne StevensMark R. BowlbyPamela L. TannenbaumJoseph BrunnerTerrence P. McdonaldAnthony L. GotterScott D. KudukPaul J. ColemanChristopher J. WinrowJohn J. Renger. (2013) Orexin Receptor Antagonists Differ from Standard Sleep Drugs by Promoting Sleep at Doses That Do Not Disrupt Cognition. Science Translational Medicine 5:179.
Crossref
Crossref
Michel A. Steiner, Carla Sciarretta, Catherine Brisbare-Roch, Daniel S. Strasser, Rolf Studer & Francois Jenck. (2013) Examining the role of endogenous orexins in hypothalamus–pituitary–adrenal axis endocrine function using transient dual orexin receptor antagonism in the rat. Psychoneuroendocrinology 38:4, pages 560-571.
Crossref
Crossref
Sarah Wurts Black, Stephen R. Morairty, Simon P. Fisher, Tsui-Ming Chen, Deepti R. Warrier & Thomas S. Kilduff. (2013) Almorexant Promotes Sleep and Exacerbates Cataplexy in a Murine Model of Narcolepsy. Sleep 36:3, pages 325-336.
Crossref
Crossref
Michel Alexander Steiner, Hugues Lecourt & François Jenck. (2013) The dual orexin receptor antagonist almorexant, alone and in combination with morphine, cocaine and amphetamine, on conditioned place preference and locomotor sensitization in the rat. International Journal of Neuropsychopharmacology 16:2, pages 417-432.
Crossref
Crossref
Matthias Hoch, Petra Hoever, Federica Alessi, Rudolf Theodor & Jasper Dingemanse. (2012) Pharmacokinetic interactions of almorexant with midazolam and simvastatin, two CYP3A4 model substrates, in healthy male subjects. European Journal of Clinical Pharmacology 69:3, pages 523-532.
Crossref
Crossref
Matthias Hoch, Justin L. Hay, Petra Hoever, Marieke L. de Kam, Erik T. te Beek, Joop M.A. van Gerven & Jasper Dingemanse. (2013) Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans. European Neuropsychopharmacology 23:2, pages 107-117.
Crossref
Crossref
Claudio E. Perez‐Leighton, Kelsey Boland, Charles J. Billington & Catherine M. Kotz. (2013) High and low activity rats: Elevated intrinsic physical activity drives resistance to diet‐induced obesity in non‐bred rats. Obesity 21:2, pages 353-360.
Crossref
Crossref
Jyrki P. Kukkonen. (2013) Physiology of the orexinergic/hypocretinergic system: a revisit in 2012. American Journal of Physiology-Cell Physiology 304:1, pages C2-C32.
Crossref
Crossref
W. Joseph HerringEllen SnyderKerry BuddJill HutzelmannDuane SnavelyKenneth LiuChristopher LinesThomas RothDavid Michelson. (2012) Orexin receptor antagonism for treatment of insomnia. Neurology 79:23, pages 2265-2274.
Crossref
Crossref
Géraldine M. Mang, Thomas Dürst, Hugo Bürki, Stefan Imobersteg, Dorothee Abramowski, Edi Schuepbach, Daniel Hoyer, Markus Fendt & Christine E. Gee. (2012) The Dual Orexin Receptor Antagonist Almorexant Induces Sleep and Decreases Orexin-Induced Locomotion by Blocking Orexin 2 Receptors. Sleep 35:12, pages 1625-1635.
Crossref
Crossref
Christopher J. Winrow, Anthony L. Gotter, Paul J. Coleman, Richard Hargreaves & John J. Renger. 2012. Drug Discovery for Psychiatric Disorders. Drug Discovery for Psychiatric Disorders
416
442
.
Daniel Hoyer & Tamas Bartfai. (2012)
Neuropeptides and Neuropeptide Receptors: Drug Targets, and Peptide and Non-Peptide Ligands: a Tribute to Prof.
Dieter Seebach
. Chemistry & Biodiversity 9:11, pages 2367-2387.
Crossref
Crossref
Claudio E. Perez-Leighton, Kelsey BolandJennifer A. Teske, Charles BillingtonCatherine M. Kotz. (2012) Behavioral responses to orexin, orexin receptor gene expression, and spontaneous physical activity contribute to individual sensitivity to obesity. American Journal of Physiology-Endocrinology and Metabolism 303:7, pages E865-E874.
Crossref
Crossref
Stephen R. Morairty, Florent G. Revel, Pari Malherbe, Jean-Luc Moreau, Daniel Valladao, Joseph G. Wettstein, Thomas S. Kilduff & Edilio Borroni. (2012) Dual Hypocretin Receptor Antagonism Is More Effective for Sleep Promotion than Antagonism of Either Receptor Alone. PLoS ONE 7:7, pages e39131.
Crossref
Crossref
John A Christopher. (2012) Orexin receptor antagonists. Pharmaceutical Patent Analyst 1:3, pages 329-346.
Crossref
Crossref
Anthony L. Gotter, Andrea L. Webber, Paul J. Coleman, John J. Renger & Christopher J. Winrow. (2012) International Union of Basic and Clinical Pharmacology. LXXXVI. Orexin Receptor Function, Nomenclature and Pharmacology. Pharmacological Reviews 64:3, pages 389-420.
Crossref
Crossref
Rong Jiang, Xinyi Song, Purva Bali, Anthony Smith, Claudia Ruiz Bayona, Li Lin, Michael D. Cameron, Patricia H. McDonald, Paul J. Kenny & Theodore M. Kamenecka. (2012) Disubstituted piperidines as potent orexin (hypocretin) receptor antagonists. Bioorganic & Medicinal Chemistry Letters 22:12, pages 3890-3894.
Crossref
Crossref
Tian-Rui Xu, Richard J. Ward, John D. Pediani & Graeme Milligan. (2012) Intramolecular Fluorescence Resonance Energy Transfer (FRET) Sensors of the Orexin OX1 and OX2 Receptors Identify Slow Kinetics of Agonist Activation. Journal of Biological Chemistry 287:18, pages 14937-14949.
Crossref
Crossref
Paul J. Coleman, John D. Schreier, Christopher D. Cox, Michael J. Breslin, David B. Whitman, Michael J. Bogusky, Georgia B. McGaughey, Rodney A. Bednar, Wei Lemaire, Scott M. Doran, Steven V. Fox, Susan L. Garson, Anthony L. Gotter, C. Meacham Harrell, Duane R. Reiss, Tamara D. Cabalu, Donghui Cui, Thomayant Prueksaritanont, Joanne Stevens, Pamela L. Tannenbaum, Richard G. Ball, Joyce Stellabott, Steven D. Young, George D. Hartman, Christopher J. Winrow & John J. Renger. (2012)
Discovery of [(2
R
,5
R
)-5-{[(5-Fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl)phenyl]methanone (MK-6096): A Dual Orexin Receptor Antagonist with Potent Sleep-Promoting Properties
. ChemMedChem 7:3, pages 415-424.
Crossref
Crossref
Anne E. Panhelainen & Esa R. Korpi. (2012) Evidence for a role of inhibition of orexinergic neurons in the anxiolytic and sedative effects of diazepam: A c-Fos study. Pharmacology Biochemistry and Behavior 101:1, pages 115-124.
Crossref
Crossref
Christopher J. Winrow, Anthony L. Gotter, Christopher D. Cox, Pamela L. Tannenbaum, Susan L. Garson, Scott M. Doran, Michael J. Breslin, John D. Schreier, Steven V. Fox, Charles M. Harrell, Joanne Stevens, Duane R. Reiss, Donghui Cui, Paul J. Coleman & John J. Renger. (2012) Pharmacological characterization of MK-6096 – A dual orexin receptor antagonist for insomnia. Neuropharmacology 62:2, pages 978-987.
Crossref
Crossref
Displaying 200 of 207 citing articles. Use the download link below to view the full list of citing articles.
Download full citations list